603718.SHG Shanghai Hile Bio-tech
- Market cap
- CNY 1.92B
- P/E
- -
- P/B
- 2.14x
- ROE
- 3.2%
- Dividend yield
- 6.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603718.SHG undervalued?
Graham numberThe Graham number of Shanghai Hile Bio-tech cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Hile Bio-tech fundamental analysis
No fundamental analysis for Shanghai Hile Bio-tech yet.
Shanghai Hile Bio-tech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent assay reagents, and re…
Full company profileShanghai Hile Bio-tech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Hile Bio-tech annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 343M | 304M | 255M | 278M | 259M | 347M | 300M | 241M | 271M | 188M | 319M |
| Gross Profit | 259M | 234M | 142M | 128M | 119M | 189M | 175M | 120M | 161M | 136M | 201M |
| Operating Income | 72.7M | 105M | 22.2M | 7.02M | -21.6M | 57.2M | 69.9M | 55.2M | 175M | 47.1M | 64.5M |
| EBITDA | 128M | 171M | 67.5M | 82.7M | 52.6M | 127M | 183M | 97.1M | 248M | -166M | 54.3M |
| Net Income | 85.5M | 114M | 21.3M | 12.2M | 8.93M | 53.9M | 122M | 62.9M | 171M | -311M | 29.0M |
| EPS | 0.13 | 0.18 | 0.03 | 0.02 | 0.01 | 0.08 | 0.19 | 0.10 | 0.26 | -0.47 | 0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.48B | 1.60B | 1.75B | 1.70B | 1.79B | 1.84B | 1.51B | 1.66B | 1.83B | 1.13B | 1.35B |
| Total Liabilities | 475M | 527M | 723M | 709M | 825M | 857M | 403M | 483M | 124M | 229M | 363M |
| Shareholders' Equity | 982M | 1.07B | 1.06B | 1.06B | 1.06B | 1.01B | 1.14B | 1.22B | 1.56B | 882M | 902M |
| Cash & Short-term Investments | 284M | 96.3M | 47.1M | 595M | 521M | 539M | 393M | 353M | 517M | 214M | 124M |
| Total Debt | 211M | 180M | 50.0M | 428M | 467M | 14.6M | 41.2M | 50.8M | 49.3M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 108M | 34.9M | 18.9M | 59.3M | 168M | 43.6M | 293M | -2.94M | 46.5M | 58.8M | - |
| Capital Expenditure | 136M | 86.0M | 112M | 39.0M | 34.1M | 37.8M | 19.8M | 7.81M | 8.39M | 12.2M | 12.1M |
| Free Cash Flow | -27.8M | -51.1M | -93.4M | 20.2M | 134M | 5.85M | 273M | -16.2M | 38.1M | 46.7M | 23.5M |
| Ratios | |||||||||||
| ROE | 8.7% | 10.6% | 2.0% | 1.1% | 0.8% | 5.4% | 10.7% | 5.2% | 11.0% | -35.3% | 3.2% |
| ROA | 5.8% | 7.1% | 1.2% | 0.7% | 0.5% | 2.9% | 8.0% | 3.8% | 9.4% | -27.7% | 2.2% |
| Net Profit Margin | 24.9% | 37.5% | 8.4% | 4.4% | 3.4% | 15.5% | 40.5% | 26.1% | 63.2% | -165.8% | 9.1% |
| Debt to Equity | 0.21x | 0.17x | 0.05x | 0.40x | 0.44x | 0.01x | 0.04x | 0.04x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Hile Bio-tech dividends
- Dividend yield
- 6.36%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 122M | 0.19 | - |
| 2024 | CNY 21.6M | 0.03 | 12.6% |
| 2023 | CNY 36.5M | 0.06 | 58.1% |
| 2022 | CNY 684K | 0.00 | 0.6% |
| 2021 | CNY 2.70M | 0.00 | 5.0% |
| 2020 | CNY 3.86M | 0.00 | 43.3% |
| 2019 | CNY 6.44M | 0.01 | 53.0% |
| 2018 | CNY 39.8M | 0.06 | 186.8% |
| 2017 | CNY 35.6M | 0.06 | 31.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 23:10 on May 5, 2016.
Who owns Shanghai Hile Bio-tech
- Insiders 40.43%
- Institutions 0.55%
- Public & others 59.02%
- Shares outstanding 649M
- Free float 348M
Shanghai Hile Bio-tech company profile
- Company name
- Shanghai Hile Bio-tech
- Ticker
- 603718.SHG
- ISIN
- CNE1000022T4
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 8, 2015
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 340
- Fiscal year end
- December
- Address
- No. 138 Huaihai Middle Road, Shanghai, China, 200001
- Phone
- 86 21 6089 0888
- Website
- hile-bio.com
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent assay reagents, and related diagnostic kits, including immunoglobulin G subtype 4, helicobacter pylori, adiponectin, creatine kinase isoenzyme, hepatobiliary acid, cardiac troponin I, heparin binding protein, N-acetyl-O-D-glucosidase, muscle soda, salivary glycan antigen KL-6 kits. It also provides oral bone repair materials, implants, natural bone repair materials, dental restorative materials, collagen-based bone repair matrix, and soft tissue repair matrix. The company was founded in 1981 and is based in Shanghai, China.
Shanghai Hile Bio-tech management
6- Mr. Benyi HanGM & Director · born 1965
- Mr. Wang XingchunFinancial Officer · born 1970
- Mr. Xiao ChenDeputy GM & Director · born 1985
- Ms. Dongchan PuDeputy GM & Secretary of the Board · born 1982
- Mr. Xiang XiaoqiangDeputy General Manager · born 1979
- Jun Qin HuangAccounting Supervisor